KRRO

12.2250.29%
AF

Andrew Fraley

Co-Founder & Advisor

Dr. Andrew Fraley, Ph.D. is Founder & Advisor of Judo Bio Inc. He is Chief of Innovation & Strategy of Radar Therapeutics Inc. He is the Co-Founder and Advisor at Frequency Therapeutics, Inc. (formerly known as Korro Bio, Inc.) and previously served as the Chief Technology Officer. Mr. Fraley has experience in the field of nucleic acid technologies and therapeutics. Mr. Fraley served as Senior Vice President of Technology of Korro Bio. Prior to Korro, Mr. Fraley was a co-founder of Triplet Therapeutics and a founding executive team member serving as SVP of translational sciences for Trucode Gene Repair, an in vivo gene editing company, leading its scientific strategy and operations. He has also served in key senior leadership roles within the biotech community, including Moderna Therapeutics, enabling the development of modified messenger RNA and Ensemble Therapeutics, providing leadership for platform development and macrocyclic discovery. He serves as Member of Scientific Advisory Board of Triplet Therapeutics, Inc. Mr. Fraley has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery and macrocyclic drug discovery. He has served as a Boston University Kindle Mentor and has consulted for government organizations, venture firms and biotech startups. He holds a B.A. from DePauw University, earned his Ph.D. in bioorganic chemistry at Boston College and was a Chateaubriand Postdoctoral Research Fellow at the University de Louis Pasteur.

Positions